# Eptinezumab in Adults With Migraine and Medication Overuse Headache

> **NCT04772742** · PHASE3 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 193 (actual)

## Conditions studied

- Migraine
- Medication Overuse Headache

## Interventions

- **DRUG:** Placebo
- **DRUG:** Eptinezumab

## Key facts

- **NCT ID:** NCT04772742
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-17
- **Primary completion:** 2022-05-23
- **Final completion:** 2022-09-30
- **Target enrollment:** 193 (ACTUAL)
- **Last updated:** 2022-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04772742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04772742, "Eptinezumab in Adults With Migraine and Medication Overuse Headache". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04772742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*